
Politicians from across the political spectrum are up in arms over healthcare giant Sanofi’s plans to sell France’s best-known medical drug Doliprane to US investors, a move critics say would lead to a “loss of sovereignty” for the country in a sensitive industry.
Trending
- Belgische ontwerper Julie Kegels geselecteerd als finalist LVMH Prize 2026
- Ireland’s Bow Street Academy Launches First LA Campus
- US Defense Secretary Hegseth: 'US blockade has gone global'
- Cyprus: How the Iran war is shaping Europe’s closest frontier to the conflict
- Meta, Microsoft purge jobs amid AI build-up
- Why Sydney Sweeney Won and ‘Michael’ Lost
- Don Cheadle, Ayo Edibiri Talk Making Broadway Debuts in ‘Proof’
- U.S. equity fund inflows rise on earnings optimism, AI boost
